Endurance Part 2

OncoPharm by OncoPharmPod

Jul 16, 202600:15:12Science & Medicine

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: Learning Oncology Companion:

Related Episodes

Continue listening to more episodes from OncoPharm.

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Aug 27, 2026 - 00:20:26

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and comm...

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...

Aug 13, 2026 - 00:16:12

Overview of renal cell carcinoma Learning Oncology Companion:

Aug 6, 2026 - 00:17:35

This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (...

Jul 30, 2026 - 00:16:32

A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesa...

Jul 23, 2026 - 00:18:16

This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib v...

Jul 9, 2026 - 00:19:18

We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-c...